2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Genitourinary
1
Gastrointestinal
1
Conditions
Recurrence
1
Neoplasm, Residual
1
Leukemia, Myeloid, Acute
1
Interventions
Cytarabine
905
Cyclophosphamide
898
fludarabine
524
venetoclax
487
fludarabine phosphate
468
Azacitidine
459
Rituximab
431
Methotrexate
419
Etoposide
320
Filgrastim
299
Busulfan
296
Dexamethasone
286
Vincristine
285
Daunorubicin
283
Peripheral Blood Stem Cell Transplantation
258
Whole-Body Irradiation
243
Mycophenolic Acid
232
Decitabine
229
Granulocyte Colony-Stimulating Factor
227
Tacrolimus
220
Imatinib Mesylate
211
Idarubicin
204
Melphalan
202
Cyclosporine
182
Doxorubicin
177
Radiotherapy
169
Prednisone
163
Dasatinib
163
Mitoxantrone
161
Lenalidomide
160
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
CD3 Complex
×
Other hematologic neoplasm
×
Clear all
NCT03038230
2025-04-06
MCLA-117 in Acute Myelogenous Leukemia
Merus B.V.
Phase 1
Terminated
80 enrolled